Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Retained Earnings: 2023-2024

Historic Retained Earnings for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to -$438.6 million.

  • Monte Rosa Therapeutics' Retained Earnings rose 4.63% to -$431.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$431.1 million, marking a year-over-year increase of 4.63%. This contributed to the annual value of -$438.6 million for FY2024, which is 19.87% down from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Retained Earnings of -$438.6 million as of FY2024, which was down 19.87% from -$365.9 million recorded in FY2023.
  • Monte Rosa Therapeutics' Retained Earnings' 5-year high stood at -$365.9 million during FY2023, with a 5-year trough of -$438.6 million in FY2024.
  • For the 2-year period, Monte Rosa Therapeutics' Retained Earnings averaged around -$402.2 million, with its median value being -$402.2 million (2023).
  • Data for Monte Rosa Therapeutics' Retained Earnings shows a maximum YoY declined of 19.87% (in 2024) over the last 5 years.
  • Over the past 2 years, Monte Rosa Therapeutics' Retained Earnings (Yearly) stood at -$365.9 million in 2023, then declined by 19.87% to -$438.6 million in 2024.